A novel biweekly schedule with cisplatin and gemcitabine in advanced non-small cell lung cancer

International Journal of Clinical Pharmacology Research

Volumn 23, Issue 1, 2003, Pages 9-16

  Lopez Vivanco G ^a   Fuente, N ^a   Barcelo R ^a   Rubio, I ^a   Munoz A ^a   Mane J M ^a   Perez Hoyos T ^a   Viteri, A ^a   Ferreiro, J ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FEMALE; HAIR LOSS; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MORTALITY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL VASCULAR DISEASE; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CONFIDENCE INTERVALS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0242364095     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Gazdar A.F., Minna J.D. Cigarettes, sex and lung adenocarcinoma. J. Natl. Cancer Inst., 89, 1563, 1997.
2. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ, 311, 899, 1995.
3. Rapp E., Pater J.L., Willan A., et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: Report of a Canadian multicenter randomized trials. J. Clin. Oncol., 6, 633, 1988.
4. Crino L., Scagliotti G.V., Ricci S., et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J. Clin. Oncol., 17, 3522, 1999.
5. Cardenal F., López-Cabrerizo M.P., Antón A., et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol., 17, 1, 1999.
6. Rosell R., Tonato M., Sandler A. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer. Semin. Oncol., 25, 27, 1998.
7. Hryniuk W. The importance of dose intensity in outcome of chemotherapy. In: Hellman S., De Vita V., Rosenberg S. (Eds.). "Important Advances in Oncology." Lippincott, Philadelphia PA, 1998, p. 121.
8. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials, 10, 1, 1989.
9. Hertel L.W., Boder G.B., Kroin J.S., et al. Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′deoxycytidine). Cancer Res., 50, 4417, 1990.
10. Hertel L.W., Kroin J.S., Misner J.W., et al. Synthesis of 2-deoxy-2′, 2′-difluoro-D-ribose and 2-deoxy-2′2′ -difluoro-D-riboturanosyl nucleosides. J. Org. Chem., 53, 2406, 1998.
11. Kelly K. The role of single-agent gemcitabine in the treatment of non-small cell lung cancer. Ann. Oncol., 10, 53, 1999.
12. Manegold C., Bergman B., Chemaissani A., et al. Single agent gemcitabine versus cisplatin/etoposide: Early results of a randomized phase II study in locally advanced or metastatic non-small cell lung cancer. Ann. Oncol., 8, 525, 1997.
13. Perng R.P., Chen Y.M., Ming-Liu K., et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a phase II randomized study. J. Clin. Oncol., 15, 2097, 1997.
14. Sandler A.B., Nemunaitis J., Denham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol., 18, 122, 2000.
15. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med., 346, 92, 2002.
16. Van Meerbeeck J.P., Smit E.F., Lianes P., et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 20, abstract no. 1228, 2001.
17. Alberola V., Camps C., Provencio M., et al. Cisplatin/Gemcitabine (CG) vs Cisplatin/Gemcitabine/Vinorelbine (CGV) vs sequential doublets of Gemcitabine/Vinorelbine followed by Ifosfamide/ Vinorelbine (GV/IV) in advanced non-small cell lung cancer: Results of a Spanish Lung Cancer Group Phase III Trial (GECP/98-02). Proc. Am. Soc. Clin. Oncol., 20, abstract no. 1229, 2001.
18. Scagliotti G.V., De Marinis F., Rinaidi M., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol., 20, 4285, 2002.
19. Soto Parra H., Cavina R., Latteri F., et al. Three-week versus four-week schedule of cisplatin and gemcitabine: Results of a randomized phase II study. Ann. Oncol., 13, 1080, 2002.
20. Barceló R., López-Vivanco G., Mañé J.M., Rubio I., Muñoz A., Fernández R. Distal ischemic changes related to combination chemotherapy with cisplatin and gemcitabine: Description of four cases. Ann. Oncol., 11, 1191, 2000.
21. Muñoz A., Mañé J.M., Rubio I., et al. Gemcitabine and vascular toxicity. Lung Cancer, 37, 229, 2002.
22. Rothenberg M.L., Sharma A., Weiss G.R., et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann. Oncol., 9, 733, 1998.
23. Colomer R., Llombart A., Lluch A., et al. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: Preliminary results of a phase II trial. Semin. Oncol., 27, (1 Suppl. 2), 20, 2000.
24. Isla D., Rosell R., Sanchez J.J., et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol., 19, 1071, 2001.
25. Hitt R., Castellano D., Cortes-Funes H., et al. Biweekly gemcitabine plus vinorelbine: A dose-finding phase I study in advanced cancer. Proc. Am. Soc. Clin. Oncol., 18, (abstract 821), 1999.
26. Denes A.E., Needles B.M., Schmidt A., et al. A comparison of two schedules of docetaxel in combination with gemcitabine given every other week. Proc. Am. Soc. Clin. Oncol., 19, (abstract 828), 2000.
27. Rigas J.R., Rothenberg M.L., Davis T.H., et al. Phase I clinical pharmacokinetic study of docetaxel with two gemcitabine infusion schedules. Proc. Am. Soc. Clin. Oncol., 18, (abstract 870), 1999.